SavedAdd your journal

Journals / Kadın Sağlığı Hemşireliği Dergisi / 2026 / Cilt: 4 Sayı: 1

AİLE PLANLAMASI YÖNTEMLERİNDE GÜNCEL GELİŞMELER

Neslihan Değerli Kodaz(SELÇUK ÜNİVERSİTESİ)
Kamile Altuntuğ(NECMETTİN ERBAKAN ÜNİVERSİTESİ)
Emel Ege(NECMETTİN ERBAKAN ÜNİVERSİTESİ)
Pages
—
Publication Date
2018-06-08
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Aile planlaması kliniklerinin kullanımı sunulan kontraseptif seçeneklerin çeşitliliği ile doğrudan ilgilidir.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Kontrasepsiyon ihtiyacı erken cinsel deneyim ve geç menopoz nedeniyle 30 yıl kadar devam etmektedir.
📊
Key Findings & Data:Kadınların birtakım farklı ihtiyaçlarının karşılanması, erken dönemde yöntem bırakmanın önlenmesi ve yöntem yan etkilerinin azaltılması amacıyla yeni kontraseptif yöntemler geliştirilmiştir.
💡
Conclusion & Impact:Aile planlaması kliniklerinin kullanımı sunulan kontraseptif seçeneklerin çeşitliliği ile doğrudan ilgilidir.
🔬Design:Derleme
📍Scope:Comprehensive Sample
⚙️Variables:Aile Planlaması · Kontrasepsiyon · Gebelik

Özet

Kontrasepsiyon ihtiyacı erken cinsel deneyim ve geç menopoz nedeniyle 30 yıl kadar devam etmektedir. Kontrasepsiyon kadınların mesleki kariyer ve çalışma planını hesaba katarak, gebeliklerini sayı ve zaman açısından planlama fırsatı verir. Güvenilir kontrasepsiyonla istenmeyen gebelik korkusu, yasa dışı düşük ve doğum kaynaklı ölümleri önlemek mümkündür. Kadınların birtakım farklı ihtiyaçlarının karşılanması, erken dönemde yöntem bırakmanın önlenmesi ve yöntem yan etkilerinin azaltılması amacıyla yeni kontraseptif yöntemler geliştirilmiştir. Kadına ait yöntemlerde yenilikler kombine kontraseptif formulasyonlar, kombine transdermal formulasyonlar, kombine kontraseptif vajinal halkalar, sadece progesteron içeren sistemler (implantlar, vajinal halkalar), bariyer yöntemler, intrauterin sistemler, histeroskopik sterilizasyon teknikleri ve acil kontrasepsiyondaki gelişmelerdir. Erkeğe ait yöntemlerde yenilikler ise hormonal yöntemler ve hormonal olmayan yöntemlerdeki gelişmelerdir. Sağlık personeli kontraseptif danışmanlıkta hasta ve kontraseptif yöntem arasındaki en iyi uyumu oluşturmak için güncel bilgiye ulaşmalıdır. Aynı zamanda, sağlık personelinin kadınlara bazı özel tıbbi durumlarda da kontraseptif sağlaması gerekebilir. Çiftlerin kendilerine uygun aile planlaması yöntemini bilerek tercih etmelerine yardım etmek için yöntemlerle ilgili bilgi verilmelidir. Aile planlaması kliniklerinin kullanımı sunulan kontraseptif seçeneklerin çeşitliliği ile doğrudan ilgilidir.

🔖

Cite This Article

Kodaz, N. D., Altuntuğ, K., Ege, E. (2018). AİLE PLANLAMASI YÖNTEMLERİNDE GÜNCEL GELİŞMELER. Kadın Sağlığı Hemşireliği Dergisi, Cilt: 4 Sayı: 1. https://ajindex.com/articles/1516222

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (80)

  1. Attardi, B. J., Engbring, J. A., Gropp, D. ve Hild, S. A., 2011, Development of Dimethandrolone 17β‐Undecanoate (DMAU) as an Oral Male Hormonal Contraceptive: Induction of Infertility and Recovery of Fertility in Adult Male Rabbits, Journal of andrology, 32 (5), 530-540.
  2. Bahamondes, L. ve Bahamondes, M. V., 2014, New and emerging contraceptives: a state-of-the-art review, International Journal of Women’s Health, 6, 221-234.
  3. Black, A., Guilbert, E., Co, A., Costescu, D., Dunn, S., Fisher, W., Kives, S., Mirosh, M., Norman, W. V., Pymar, H., Reid, R., Roy, G., Varto, H., Waddington, A., Wagner, M. S., Whelan, A. M., Special, C., Ferguson, C., Fortin, C., Kielly, M., Mansouri, S. ve Todd, N., 2015, Canadian Contraception Consensus (Part 2 of 4), J Obstet Gynaecol Can, 37 (11), 1033-1039.
  4. Bonnema, R. A. ve Spencer, A. L., 2011, The new extended-cycle levonorgestrel-ethinyl estradiol oral contraceptives, Clin Med Insights Reprod Health, 5, 49-54.
  5. Brache, V., Croxatto, H., Kumar, N., Sitruk-Ware, R., Cochón, L., Schiappacasse, V., Sivin, I., Muñoz, C., Maguire, R. ve Faundes, A., 2009, Effect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard gel: a randomized, cross-over, pharmacokinetic study, Contraception, 79 (2), 150-154.
  6. Brache, V., Merkatz, R., Kumar, N., Jesam, C., Sussman, H., Hoskin, E., Roberts, K., Alami, M., Taylor, D., Jorge, A., Croxatto, H., Lorange, E., Mishell, D. R. ve Sitruk-Ware, R., 2015, A dose-finding, cross-over study to evaluate the effect of a Nestorone(R)/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women, Contraception, 92 (4), 289-297.
  7. Calliope, 2017, The Contraceptive Pipeline Database, https://pipeline.ctiexchange.org/products?&&&&&&&&&field sponsors tid[0]=471
  8. Chaki, S. P., Das, H. C. ve Misro, M. M., 2003, A short-term evaluation of semen and accessory sex gland function in phase III trial subjects receiving intravasal contraceptive RISUG, Contraception, 67 (1), 73–78.
  9. Cheng, L., Che, Y. ve Gülmezoglu, A. M., 2012, Interventions for emergency contraception, Cochrane Database of Systematic Reviews (8), CD001324.
  10. Clark, J. T., Clark, M. R., Shelke, N. B., Johnson, T. J., Smith, E. M., Andreasen, A. K., Nebeker, J. S., Fabian, J., Friend, D. R. ve Kiser, P. F., 2014, Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy, PLoS One, 9 (3), e88509.
  11. Contraceptive Independence, 2016, Jadelle®Contraceptive Independence, http://www.jadelle.com/static/documents/Jadelle General Brochure.pdf
  12. Cox, M., Tripp, J. ve Blacksell, S., 2002, Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report, Journal of Family Planning and Reproductive Health Care, 28 (2), 73-77.
  13. Dhont, M., 2010, History of oral contraception, Eur J Contracept Reprod Health Care, 15 Suppl 2, S12-18.
  14. Doğum Kontrol Flasteri (Evra), 2016, Doğum Kontrol Flasteri (Evra) http://www.e-gebelik.net/aile%20planlamasi/yeni yontemler/dogum kontrol flasteri evra.asp
  15. Doğum Kontrol Metodları, 2016, Doğum Kontrol Metodları, http://www.dr-hsenyurt.com/dogum-kontrol.html
  16. Evlilik Öncesi Danışmanlık Rehberi, 2014, Evlilik Öncesi Danışmanlık Rehberi, http://sbu.saglik.gov.tr/Ekutuphane/kitaplar/Evlilikoncesi%20DanismanlikRehberi.pdf
  17. FDA Approved Drug Products, 2001, Drugs@FDA FDA Approved Drug Products, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
  18. Fraser, I. S., Weisberg, E., Kumar, N., Kumar, S., Humberstone, A. J., McCrossin, L., Shaw, D., Tsong, Y. Y. ve Sitruk-Ware, R., 2007, An initial pharmacokinetic study with a Metered Dose Transdermal Systemfor delivery of the progestogen Nestorone as a possible future contraceptive, Contraception, 76 (6), 432-438.
  19. Goldstuck, N. D., 2014, Reducing Barriers to the use of the Intrauterine Contraceptive Device as a Long Acting Reversible Contraceptive, African Journal of Reproductive Health, 18 (4), 15-25.
  20. Gu, Y., Liang, X., Wu, W., Liu, M., Song, S., Cheng, L., Bo, L., Xiong, C., Wang, X., Liu, X., Peng, L. ve Yao, K., 2009, Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men, J Clin Endocrinol Metab, 94 (6), 1910-1915.
  21. Hamburg, M. A., 2011, Premarket Approval of Pediatric Uses of Devices – FY 2009-2011, U.S. Department of Health and Human Services.
  22. Highlights of Prescribing Information, 2015, Highlights of Prescribing Information, http://labeling.bayerhealthcare.com/html/products/pi/natazia pi.pdf
  23. Hofmeyr, G. J., Singata, M. ve Lawrie, T. A., 2010, Copper containing intra-uterine devices versus depot progestogens for contraception., Cochrane Database of Systematic Reviews, 16 (6), CD007043.
  24. Huang, Y., Jensen, J. T., Brache, V., Cochon, L., Williams, A., Miranda, M. J., Croxatto, H., Kumar, N., Sussman, H., Hoskin, E., Plagianos, M., Roberts, K., Merkatz, R., Blithe, D. ve Sitruk-Ware, R., 2014, A randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: research for a novel estrogen-free, method of contraception, Contraception.
  25. Hugon-Rodin, J., Chabbert-Buffet, N. ve Bouchard, P., 2010, The future of women’s contraception: stakes and modalities, Annals of the New York Academy of Sciences, 1205, 230-239.
  26. Ilani, N., Roth, M. Y., Amory, J. K., Swerdloff, R. S., Dart, C., Page, S. T., Bremner, W. J., Sitruk-Ware, R., Kumar, N., Blithe, D. L. ve Wang, C., 2012, A New Combination of Testosterone and Nestorone Transdermal Gels for Male Hormonal Contraception, Journal of Clinical Endocrinology & Metabolism, 97 (10), 3476-3486.
  27. Implanon, 2016, Implanon™ http://www.accessdata.fda.gov/drugsatfda docs/label/2009/021529s004lbl.pdf
  28. Jacobson, J. C., Likis, F. E. ve Murphy, P. A., 2012, Extended and continuous combined contraceptive regimens for menstrual suppression, J Midwifery Womens Health, 57 (6), 585-592.
  29. Jadav, S. P. ve Parmar, D. M., 2012, Ulipristal acetate, a progesterone receptor modulator for emergency contraception, J Pharmacol Pharmacother, 3 (2), 109-111.
  30. Jensen, J. T., 2011, The future of contraception: innovations in contraceptive agents: tomorrow's hormonal contraceptive agents and their clinical implications, Am J Obstet Gynecol, 205 (4 Suppl), S21-25.
  31. Koyama, A., Hagopian, L. ve Linden, J., 2013, Emerging options for emergency contraception, Clin Med Insights Reprod Health, 7, 23-35.
  32. Lawrie, T. A., Nardin, J. M., Kulier, R. ve Boulvain, M., 2011, Techniques for the interruption of tubal patency for female sterilisation, Cochrane Database Syst Rev., 16 (2), CD003034.
  33. Lendvay, A., Otieno-Masaba, R., Azmat, S. K., Wheeless, A., Hameed, W., Shaikh, B. T., Kuria, S., Steiner, M. J., Chen, M. ve Feldblum, P. J., 2014, Effectiveness, safety and acceptability of Sino-implant (II) during the first year of use: results from Kenya and Pakistan, Contraception, 89 (3), 197-203.
  34. Leoci, R., Aiudi, G., Silvestre, F., Lissner, E. A., Marino, F. ve Lacalandra, G. M., 2015, Therapeutic Ultrasound as a Potential Male Dog Contraceptive: Determination of the Most Effective Application Protocol, Reproduction in Domestic Animals, 50 (5), 712-718.
  35. Levonorgestrel Releasing Intrauterine System, 2013, Levonorgestrel, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
  36. Levonorgestrel Releasing Intrauterine System, 2016, Levonorgestrel Releasing Intrauterine System, http://www.accessdata.fda.gov/drugsatfda docs/label/2008/021225s019lbl.pdf
  37. LNG ICD, 2017, Levonorgestrel (LNG) Intracervical Device (ICD), https://pipeline.ctiexchange.org/products/lng-icd
  38. Lopez, L. M., Grimes, D. A., Gallo M, F., Stockton, L. L. ve Schulz, K. F., 2013, Skin patch and vaginal ring versus combined oral contraceptives for contraception, Cochrane Database of Systematic Reviews, 30 (4), CD003552.
  39. Lu, W. H., Liang, X. W., Gu, Y. Q., Wu, W. X., Bo, L. W., Zheng, T. G. ve Chen, Z. W., 2014, A randomized, controlled, multicenter contraceptive efficacy clinical trial of the intravas device, a nonocclusive surgical male sterilization, Asian J Androl, 16 (3), 432-436.
  40. Magon, N., Chauhan, M., Goel, P., Malik, S., Kapur, K., Kriplani, A., Dhaliwal, L. ve Pandit, S. N., 2013, Levonorgestrel intrauterine system: Current role in management of heavy menstrual bleeding, J Midlife Health, 4 (1), 8-15.
  41. malecontraceptives, 2016, malecontraceptives.org, https://www.malecontraceptive.org/
  42. Meirik, O., Rowe, P. J., Peregoudov, A., Piaggio, G., Petzold, M., Iud Research Group at the Undp/Unfpa/Who/World Bank Special Programme of Research, D. ve Research Training in Human, R., 2009, The frameless copper IUD (GyneFix) and the TCu380A IUD: results of an 8-year multicenter randomized comparative trial, Contraception, 80 (2), 133-141.
  43. Mifeprex, 2000, Mifeprex, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
  44. Mifeprex (mifepristone) Information, 2016, Mifeprex (mifepristone) Information, http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111323.htm
  45. Mohamed, A. M., El-Sherbiny, W. S. ve Mostafa, W. A., 2011, Combined contraceptive ring versus combined oral contraceptive (30-µg ethinylestradiol and 3-mg drospirenone), International Journal of Gynecology and Obstetrics, 114 (2), 145-148.
  46. Mulders, T. M., Dieben, T. O. ve Bennink, H. J., 2002, Ovarian function with a novel combined contraceptive vaginal ring., Hum Reprod, 17 (10), 2594-2599
  47. NES Implant, 2016, NES Implant, http://pipeline.ctiexchange.org/products/nes-implant
  48. Nestorone/Estradiol Transdermal Gel Contraception, 2016, Nestorone®/Estradiol Transdermal Gel Contraception, http://www.popcouncil.org/research/nestorone-estradiol-transdermal-gel-contraception
  49. Nexplanon, 2016, Nexplanon, http://www.accessdata.fda.gov/drugsatfda docs/label/2015/021529s011lbl.pdf
  50. Nuvaring Vajinal Halka, 2005, Nuvaring Vajinal Halka, http://www.msd.com.tr/Style%20Library/CountrySite/Turkey/Turkish/pdfs/NUVARING Vajinal Halka KUB.pdf
  51. Obare, F., Rajamani, D. ve S., R., 2014, Assessing the potential market for a progesterone contraceptive vaginal ring (pcvr) as a new contraceptıve option in sub-saharan africa using needs-based market segmentatıon.
  52. One size contraceptive diaphragm, 2016, New Product Review from the Clinical Effectiveness Unit One size contraceptive diaphragm (Caya®), https://www.google.com.tr/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwiZsKrBxJnTAhVD6xoKHZ7dCHYQFggeMAA&url=https%3A%2F%2Fwww.fsrh.org%2Fdocuments%2Fcec-ceu-newproductreview-caya-aug-2014%2Fcec-ceu-newproductreview-caya-aug-2014.pdf&usg=AFQjCNE4wwvnzohLQds1AO7MlcnTwJ57HA&bvm=bv.152180690,d.d2s
  53. Oral Contraceptive Reference Chart, 2014, Oral Contraceptive Reference Chart, http://www.rmhp.org/docs/default-source/provider/oral contraceptive reference chart.pdf?sfvrsn=7
  54. Piaggio, G., Kapp, N. ve von Hertzen, H., 2011, Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trials, Contraception, 84 (1), 35-39.
  55. Population Council, 2016, Population Council, http://www.popcouncil.org/
  56. Rahim İçi Araçlar, 2016, Rahim İçi Araçlar, http://sbu.saglik.gov.tr/Ekutuphane/kitaplar/a%C3%A7sap35.pdf
  57. Roth, M. Y., Shih, G., Ilani, N., Wang, C., Page, S. T., Bremner, W. J., Swerdloff, R. S., Sitruk-Ware, R., Blithe, D. L. ve Amory, J. K., 2014, Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial, Contraception, 90 (4), 407-412.
  58. Sanhal, C. Y., Ulukuş, M. ve İtil, İ. M., 2012, Kontrasepsiyonda Güncel Gelişmeler, Türk Jinekoloji ve Obstetrik Derneği Dergisi, 9 (2 ), 85- 93.
  59. Schuurman, T. ve Veersema, S., 2011, Successful placement of the Essure device after a failed procedure using the Adiana system for hysteroscopic sterilisation, BMJ Case Rep, 2011.
  60. Sitruk-Ware, R., Small, M., Kumar, N., Tsong, Y. Y., Sundaram, K. ve Jackanicz, T., 2003, Nestorone®: clinical applications for contraception and HRT, Steroids, 68 (10-13), 907-913.
  61. Sitruk-Ware, R., Brache, V., Maguire, R., Croxatto, H., Kumar, N., Kumar, S., Montero, J. C., Salvatierra, A. M., Phillips, D. ve Faundes, A., 2007, Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for "dual protection" contraception, Contraception, 75 (6), 454-460.
  62. Sitruk-Ware, R., Nath, A. ve Mishell, D. R., Jr., 2013, Contraception technology: past, present and future, Contraception, 87 (3), 319-330.
  63. Skyla, 2016, Skyla, http://www.skyla-us.com/index.php
  64. Summary of Safety and Effectıveness Data, 2002, Summary of Safety and Effectıveness Data, http://www.accessdata.fda.gov/cdrh docs/pdf2/p020014b.pdf
  65. Taylor, T. N., Farkouh, R. A., Graham, J. B., Colligs, A., Lindemann, M., Lynen, R. ve Candrilli, S. D., 2011, Potential reduction in neural tube defects associated with use of Metafolin-fortified oral contraceptives in the United States, Am J Obstet Gynecol, 205 (5), 460 e461-468.
  66. Thakur, V., Choudhary, M., Mehta, V. ve Kumar, D., 2013, RISUG: A new perspective in non–hormonal male contraception, Asian Pacific Journal of Reproduction, 2 (2), 159–162.
  67. The Essure Permanent Birth Control System, 2016, A New Method of Permanent Birth Control: The essure Permanent Birth Control System, http://www.fda.gov/ohrms/dockets/ac/02/briefing/3881b1 04.pdf
  68. Today sponge contraceptive sponge, 2007, Today sponge contraceptive sponge http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi id=874974
  69. Trussell, J., Raymond, E. G. ve Cleland, K., 2014, Emergency contraception: a last chance to prevent unintended pregnancy, Contemp. Readings L. & Soc. Just., 6, 7.
  70. Türk, R. ve Terzioğlu, F., 2012, Geri Çekme Yöntemi ve Kullanımını Etkileyen Faktörler, Ankara Sağlık Bilimleri Dergisi, 1 (3), 67-80.
  71. Türkiye Nüfus ve Sağlık Araştırması, 2013, Türkiye Nüfus ve Sağlık Araştırması, Hacettepe Üniversitesi Nüfus Etütleri Enstitüsü.
  72. Ulipristal Acetate, 2010, Ulipristal Acetate, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
  73. US Food and Drug Administration, 2001, U.S. Food and Drug Administration, http://www.fda.gov/default.htm
  74. VandeVoort, C. A. ve Tollner, T. L., 2012, The efficacy of ultrasound treatment as a reversible male contraceptive in the rhesus monkey, Reproductive Biology and Endocrinology, 10.
  75. Vasalgel Faq’s, 2016, Vasalgel Faq’s, http://www.parsemusfoundation.org/projects/vasalgel/vasalgel-faqs
  76. What is essure, 2016, What is essure, www.essure.com/what-is-essure
  77. Wildemeersch, D., 2007, New frameless and framed intrauterine devices and systems - an overview, Contraception, 75 (6 Suppl), S82-S92.
  78. Wildemeersch, D., Janssens, D. ve Andrade, A., 2009, The Femilis LNG-IUS: contraceptive performance-an interim analysis, European Journal of Contraception and Reproductive Health Care, 14 (2), 103-110.
  79. Wildemeersch, D. ve Andrade, A., 2010, Review of clinical experience with the frameless LNG-IUS for contraception and treatment of heavy menstrual bleeding, Gynecol Endocrinol, 26 (5), 383-389.
  80. Wildemeersch, D., 2012, The LNG-IUS: The First Choice Alternative to Hysterectomy? Intrauterine Levonorgestrel-Releasing Systems for Effective Treatment and Contraception, INTECH Open Access Publisher.